Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Ummanni, Ramesh ^a   Jost, Edgar ^b   Braig, Melanie ^a   Lohmann, Frithjof ^a   Mundt, Frederike ^a   Barett, Christine ^a   Schlomm, Thorsten ^a   Sauter, Guido ^a   Senff, Tina ^b   Bokemeyer, Carsten ^a   Sültmann, Holger ^c   Meyer Schwesinger, Catherine ^a   Brümmendorf, Tim H ^a,b   Balabanov, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Prostate cancer; Signalling; Tumour suppression; Ubiquitin system; Uchl1

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN CARBOXYL TERMINAL HYDROLASE 1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN KINASE B; TP53 PROTEIN, HUMAN; UCHL1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL AGING; CELL GROWTH; CELL PROLIFERATION; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PYROSEQUENCING; UBIQUITINATION; CELL ADHESION; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

CELL ADHESION; CELL AGING; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 80053973302     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-129     Document Type: Article

References (42)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8-31. 1, 10.3322/canjclin.49.1.8, 10200775.
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006, 11:1388-1413. 10.2741/1891, 16368524.
3. Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Falth M, Kollermann J, Walther R, Schlomm T, et al. Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform. PLoS One 2011, 6:e16833. 10.1371/journal.pone.0016833, 3037937, 21347291.
4. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005, 6:599-609. 10.1038/nrm1700, 16064136.
5. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397. 10.1146/annurev.biochem.78.082307.091526, 2734102, 19489724.
6. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009, 10:550-563. 10.1038/nrm2731, 19626045.
7. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786. 10.1016/j.cell.2005.11.007, 16325574.
8. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000, 6:4764-4767.
9. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999, 155:711-715. 10.1016/S0002-9440(10)65169-3, 1866887, 10487828.
10. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002, 8:192-195.
11. Liu X, Zeng B, Ma J, Wan C. Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 2009, 27:345-352. 10.1080/07357900802438577, 19212829.
12. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 2003, 50:1278-1280.
13. Lee YM, Lee JY, Kim MJ, Bae HI, Park JY, Kim SG, Kim DS. Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 2006, 97:1205-1210. 10.1111/j.1349-7006.2006.00320.x, 16965602.
14. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005, 65:4963-4968. 10.1158/0008-5472.CAN-04-3923, 15930319.
15. Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006, 106:483-493. 10.1002/cncr.21657, 16362978.
16. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y, Song JH, Gui D, Said J, Koeffler HP. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 2009, 124:827-833. 10.1002/ijc.23994, 19035457.
17. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ, Lee KJ. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009, 28:117-127. 10.1038/onc.2008.364, 18820707.
18. Bheda A, Yue W, Gullapalli A, Whitehurst C, Liu R, Pagano JS, Shackelford J. Positive reciprocal regulation of ubiquitin C-terminal hydrolase L1 and beta-catenin/TCF signaling. PLoS One 2009, 4:e5955. 10.1371/journal.pone.0005955, 2694282, 19536331.
19. Bheda A, Shackelford J, Pagano JS. Expression and functional studies of ubiquitin C-terminal hydrolase L1 regulated genes. PLoS One 2009, 4:e6764. 10.1371/journal.pone.0006764, 2729380, 19707515.
20. Li L, Tao Q, Jin H, van HA, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT, et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 2010, 16:2949-2958. 10.1158/1078-0432.CCR-09-3178, 20395212.
21. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006, 119:1338-1344. 10.1002/ijc.22025, 16642472.
22. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665. 10.1038/nature03841, 16079837.
23. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I. Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 2007, 67:1761-1769. 10.1002/pros.20654, 17929277.
24. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, Todo S, Hirohashi S. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002, 62:2971-2975.
25. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245. 10.1073/pnas.96.8.4240, 33561, 10200246.
26. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998, 95:15587-15591. 10.1073/pnas.95.26.15587, 28087, 9861013.
27. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, Charoenrat P, Levine AJ, Rao PH, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002, 16:984-993. 10.1101/gad.973602, 152354, 11959846.
28. Kuo ML, Duncavage EJ, Mathew R, den BW, Pei D, Naeve D, Yamamoto T, Cheng C, Sherr CJ, Roussel MF. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003, 63:1046-1053.
29. Agrawal A, Yang J, Murphy RF, Agrawal DK. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol 2006, 81:115-122. 10.1016/j.yexmp.2006.07.001, 16919268.
30. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 2008, 123:753-759. 10.1002/ijc.23354, 3069849, 18512240.
31. Gartel AL. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 2005, 29:1237-1238. 10.1016/j.leukres.2005.04.023, 15946739.
32. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005, 65:3980-3985. 10.1158/0008-5472.CAN-04-3995, 15899785.
33. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
34. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14:146-155. 10.1016/j.ccr.2008.06.002, 2583442, 18691549.
35. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM. Senescence-associated exosome release from human prostate cancer cells. Cancer Res 2008, 68:7864-7871. 10.1158/0008-5472.CAN-07-6538, 18829542.
36. Caballero OL, Resto V, Patturajan M, Meerzaman D, Guo MZ, Engles J, Yochem R, Ratovitski E, Sidransky D, Jen J. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene 2002, 21:3003-3010. 10.1038/sj.onc.1205390, 12082530.
37. Nho RS, Sheaff RJ. p27kip1 contributions to cancer. Prog Cell Cycle Res 2003, 5:249-259.
38. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol 2003, 13:65-70. 10.1016/S0962-8924(02)00043-0, 12559756.
39. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001, 264:148-168. 10.1006/excr.2000.5143, 11237531.
40. Guadagno TM, Ohtsubo M, Roberts JM, Assoian RK. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 1993, 262:1572-1575. 10.1126/science.8248807, 8248807.
41. Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, Sicinski P. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci USA 2001, 98:194-199. 10.1073/pnas.011522998, 14567, 11134518.
42. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 1996, 133:391-403. 10.1083/jcb.133.2.391, 2120799, 8609171.